CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results - PubMed
4 hours ago
- #Pediatric Oncology
- #CAR T-cell therapy
- #B-ALL
- Bivalent CD19/CD22 CAR T-cell therapy targets multiple antigens to reduce antigen escape in B-ALL.
- Phase 1 trial involved children, adolescents, and young adults aged 3–39 with relapsed/refractory B-ALL.
- At the recommended phase 2 dose, 71.4% of B-ALL patients developed cytokine release syndrome (CRS), mostly low-grade.
- Initial construct showed limited CD22 recognition but had a tolerable safety profile and demonstrated efficacy.